Fall 2026

Chemistry Intern

Posted on 7/27/2026

Inductive Bio

Inductive Bio

11-50 employees

ML-driven software for small molecule ADMET

Compensation Overview

$20 - $30/hr

Woburn, MA, USA

In Person

Category
Lab & Research (1)

Get referred to Inductive Bio

See people who can refer or advise you

Requirements
  • Recently completed or currently pursuing a Bachelor's degree in Chemistry or a related scientific field.
  • Experience working in a laboratory environment through coursework or undergraduate research.
  • Ability to follow written procedures accurately and safely.
  • Ability to work reliably, stay organized, and maintain attention to detail.
Responsibilities
  • Receive hands-on training in laboratory safety, best practices, and synthetic chemistry techniques.
  • Learn standardized chemistry reactions, protocols, and laboratory workflows.
  • Run experiments independently by measuring reagents, mixing, heating, cooling, and preparing samples for analysis.
  • Operate laboratory instrumentation, process samples, and support experimental workflows.
  • Document experimental observations and results accurately.
  • Contribute to testing how artificial intelligence and standardized workflows can accelerate drug discovery.

Inductive Bio uses machine learning on a proprietary, curated dataset to help pharmaceutical, biotech, and research teams design small molecule drugs. Its platform provides real-time ADMET predictions and data-driven insights to guide drug design throughout development. The system stands out by pairing a thoroughly curated ADMET dataset with ML models in a user-friendly platform that supports entire teams, not just data scientists. The goal is to accelerate the discovery and optimization of safe, effective small molecule drugs by delivering practical, data-driven guidance during development.

Company Size

11-50

Company Stage

Series A

Total Funding

$29.3M

Headquarters

San Francisco, California

Founded

2021

Get referred to Inductive Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Early optimization of dose, safety margins, and developability accelerates small molecule discovery using top-ranked ML models trained on diverse ADMET data[4].
  • Collaborations with pharma partners like Nested Therapeutics demonstrate ML-ADMET success in reducing synthesized compounds and accelerating lead optimization[9].
  • Funding of $25M Series A led by Obvious Ventures supports expansion of AI platform Compass for predicting drug behavior before synthesis[4].

What critics are saying

  • Anthropic and a16z-backed competitors will integrate ADMET prediction into LLM workflows, undercutting standalone software value within 9–15 months with 45–60% probability.
  • Big Pharma will build in-house ADMET models using proprietary data silos, making Inductive Bio's consortium redundant within 12–18 months with 35–50% probability.
  • DATAMAP project failure due to organoid data variability or FDA delays will strip credibility from AI toxicity claims within 6–12 months with 25–40% probability.

What makes Inductive Bio unique

  • Inductive Bio's Beacon ADMET and PK models rank first among 370+ entries in the OpenADMET-ExpansionRx blind challenge[4].
  • The company leverages the industry's largest unified ADMET dataset from its pre-competitive consortium to power accurate predictions across wide chemical space[5].
  • Its Compass platform enables millions of in silico experiments to predict molecular behavior long before clinical entry, reducing preclinical time and costs[5].

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Commuter Benefits

Phone/Internet Stipend

Home Office Stipend

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Unlimited Paid Time Off

401(k) Retirement Plan

401(k) Company Match

Company Equity

Stock Options

Wellness Program

Mental Health Support

Professional Development Budget

Conference Attendance Budget

Tuition Reimbursement

Professional Certification Support

Training Programs

Pet Insurance

Adoption Assistance

Family Planning Benefits

Fertility Treatment Support

Parental Leave

Relocation Assistance

Employee Discounts

Meal Benefits

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

5%

2 year growth

-5%
Inductive Bio
Dec 9th, 2025
Inductive Bio Announces an up to $21M Award to Develop AI Drug Toxicity Models

Team to develop and validate computational models trained on data from organoids and advanced human model systems that will improve drug safety and reduce reliance on animal testing

Third News
Dec 8th, 2025
Inductive Bio secures $21M to develop AI drug toxicity models reducing animal testing

Inductive Bio has secured up to $21 million in funding to develop AI-driven drug toxicity models that could transform safety assessments in drug discovery. The initiative, called DATAMAP, involves collaboration with Amgen, Cincinnati Children's Hospital Medical Center, Baylor College of Medicine and Torch Bio. The project aims to reduce reliance on animal testing by using human-derived data from organoid systems to predict drug safety more accurately. Currently, nearly 90% of clinical-stage drug candidates fail to reach market, with 25% failing due to unforeseen safety issues. The initial phase will focus on drug-induced liver injury and cardiotoxicity, which account for over 40% of drug withdrawals. Inductive Bio will work with the FDA to validate these AI models for regulatory approval, aligning with the agency's push to modernise drug development methodologies.

AlleyWatch
May 16th, 2025
Inductive Bio Raises $25M for AI Drug Discovery

Inductive Bio has secured $25M in Series A funding led by Obvious Ventures, with participation from a16z Bio + Health, Lux Capital, and others. The company aims to transform drug discovery with its collaborative AI platform, which accelerates compound optimization by predicting molecular behavior before lab synthesis. This approach reduces costs and speeds up drug development. Inductive Bio's platform has shown success in the Polaris ADMET competition and plans to expand its team and platform reach.

FinSMEs
May 7th, 2025
Inductive Bio Raises $25M in Series A Funding

Inductive Bio raises $25M in Series A funding.

BiopharmaTrend
May 7th, 2025
Inductive Bio Raises $25M to Scale AI Platform for Predicting Drug Behavior Before Synthesis

Inductive Bio has secured $25 million in Series A financing to expand its machine learning platform for small molecule drug discovery.